These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 26011469)

  • 1. A Cluster of Proteins Implicated in Kidney Disease Is Increased in High-Density Lipoprotein Isolated from Hemodialysis Subjects.
    Shao B; de Boer I; Tang C; Mayer PS; Zelnick L; Afkarian M; Heinecke JW; Himmelfarb J
    J Proteome Res; 2015 Jul; 14(7):2792-806. PubMed ID: 26011469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parallel reaction monitoring (PRM) and selected reaction monitoring (SRM) exhibit comparable linearity, dynamic range and precision for targeted quantitative HDL proteomics.
    Ronsein GE; Pamir N; von Haller PD; Kim DS; Oda MN; Jarvik GP; Vaisar T; Heinecke JW
    J Proteomics; 2015 Jan; 113():388-99. PubMed ID: 25449833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxidative stress and high-density lipoprotein function in Type I diabetes and end-stage renal disease.
    Kalogerakis G; Baker AM; Christov S; Rowley KG; Dwyer K; Winterbourn C; Best JD; Jenkins AJ
    Clin Sci (Lond); 2005 Jun; 108(6):497-506. PubMed ID: 15634192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uremia alters HDL composition and function.
    Holzer M; Birner-Gruenberger R; Stojakovic T; El-Gamal D; Binder V; Wadsack C; Heinemann A; Marsche G
    J Am Soc Nephrol; 2011 Sep; 22(9):1631-41. PubMed ID: 21804091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted Proteomics Identifies Paraoxonase/Arylesterase 1 (PON1) and Apolipoprotein Cs as Potential Risk Factors for Hypoalphalipoproteinemia in Diabetic Subjects Treated with Fenofibrate and Rosiglitazone.
    Ronsein GE; Reyes-Soffer G; He Y; Oda M; Ginsberg H; Heinecke JW
    Mol Cell Proteomics; 2016 Mar; 15(3):1083-93. PubMed ID: 26667175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dysfunctional high-density lipoprotein in patients on chronic hemodialysis.
    Yamamoto S; Yancey PG; Ikizler TA; Jerome WG; Kaseda R; Cox B; Bian A; Shintani A; Fogo AB; Linton MF; Fazio S; Kon V
    J Am Coll Cardiol; 2012 Dec; 60(23):2372-9. PubMed ID: 23141484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low clusterin levels in high-density lipoprotein associate with insulin resistance, obesity, and dyslipoproteinemia.
    Hoofnagle AN; Wu M; Gosmanova AK; Becker JO; Wijsman EM; Brunzell JD; Kahn SE; Knopp RH; Lyons TJ; Heinecke JW
    Arterioscler Thromb Vasc Biol; 2010 Dec; 30(12):2528-34. PubMed ID: 20847305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantification of HDL proteins, cardiac events, and mortality in patients with type 2 diabetes on hemodialysis.
    Kopecky C; Genser B; Drechsler C; Krane V; Kaltenecker CC; Hengstschläger M; März W; Wanner C; Säemann MD; Weichhart T
    Clin J Am Soc Nephrol; 2015 Feb; 10(2):224-31. PubMed ID: 25424990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma concentrations of non-esterified fatty acids in chronic renal failure in the United Arab Emirates.
    Gillett MP; Obineche EN; Khan ST; Abdulle AM
    Saudi Med J; 2004 Nov; 25(11):1611-6. PubMed ID: 15573187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased carbamylation level of HDL in end-stage renal disease: carbamylated-HDL attenuated endothelial cell function.
    Sun JT; Yang K; Lu L; Zhu ZB; Zhu JZ; Ni JW; Han H; Chen N; Zhang RY
    Am J Physiol Renal Physiol; 2016 Mar; 310(6):F511-7. PubMed ID: 26764205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-density lipoprotein loses its anti-inflammatory capacity by accumulation of pro-inflammatory-serum amyloid A.
    Tölle M; Huang T; Schuchardt M; Jankowski V; Prüfer N; Jankowski J; Tietge UJ; Zidek W; van der Giet M
    Cardiovasc Res; 2012 Apr; 94(1):154-62. PubMed ID: 22328092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Albuminuria, the High-Density Lipoprotein Proteome, and Coronary Artery Calcification in Type 1 Diabetes Mellitus.
    Shao B; Zelnick LR; Wimberger J; Himmelfarb J; Brunzell J; Davidson WS; Snell-Bergeon JK; Bornfeldt KE; de Boer IH; Heinecke JW
    Arterioscler Thromb Vasc Biol; 2019 Jul; 39(7):1483-1491. PubMed ID: 31092010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL.
    Vaisar T; Pennathur S; Green PS; Gharib SA; Hoofnagle AN; Cheung MC; Byun J; Vuletic S; Kassim S; Singh P; Chea H; Knopp RH; Brunzell J; Geary R; Chait A; Zhao XQ; Elkon K; Marcovina S; Ridker P; Oram JF; Heinecke JW
    J Clin Invest; 2007 Mar; 117(3):746-56. PubMed ID: 17332893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-high-density lipoprotein cholesterol (non-HDL-C) as a predictor of cardiovascular mortality in patients with end-stage renal disease.
    Nishizawa Y; Shoji T; Kakiya R; Tsujimoto Y; Tabata T; Ishimura E; Nakatani T; Miki T; Inaba M
    Kidney Int Suppl; 2003 May; (84):S117-20. PubMed ID: 12694324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantifying HDL proteins by mass spectrometry: how many proteins are there and what are their functions?
    Shao B; Heinecke JW
    Expert Rev Proteomics; 2018 Jan; 15(1):31-40. PubMed ID: 29113513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dialysis Modalities and HDL Composition and Function.
    Holzer M; Schilcher G; Curcic S; Trieb M; Ljubojevic S; Stojakovic T; Scharnagl H; Kopecky CM; Rosenkranz AR; Heinemann A; Marsche G
    J Am Soc Nephrol; 2015 Sep; 26(9):2267-76. PubMed ID: 25745027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alteration of plasma total F2-isoprostanes before and after hemodialysis in end-stage renal disease patients.
    Kim KM; Jung BH; Paeng KJ; Kim SW; Chung BC
    Prostaglandins Leukot Essent Fatty Acids; 2004 May; 70(5):475-8. PubMed ID: 15062851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma angiopoietin-like protein 3 (ANGPTL3) concentration is associated with uremic dyslipidemia.
    Shoji T; Hatsuda S; Tsuchikura S; Kimoto E; Kakiya R; Tahara H; Koyama H; Emoto M; Tabata T; Nishizawa Y
    Atherosclerosis; 2009 Dec; 207(2):579-84. PubMed ID: 19540497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arterial stiffness in predialysis patients with uremia.
    Shinohara K; Shoji T; Tsujimoto Y; Kimoto E; Tahara H; Koyama H; Emoto M; Ishimura E; Miki T; Tabata T; Nishizawa Y
    Kidney Int; 2004 Mar; 65(3):936-43. PubMed ID: 14871413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure.
    Attman PO; Alaupovic P; Tavella M; Knight-Gibson C
    Nephrol Dial Transplant; 1996 Jan; 11(1):63-9. PubMed ID: 8649654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.